HJHamza Jamil

Hamza Jamil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hamza Jamil has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Transcriptomic Analysis for Elucidating the Therapeutic Potential of Sitagliptin Against the Identified TOP2A/UBE2C/CKS2 Genes as Mutually Inclusive Theragnostic Signatures of Bladder and Prostate Cancer

    by Muhammad Naveed, Muhammad Saad Mughal, Tariq Aziz, Syed Izma Makhdoom, Hamza Jamil, Ayaz Ali Khan, Taqweem Ul Haq, Abdulhakeem S. Alamri, Walaa F. Alsanie, Majid Alhomrani

    Bladder and prostate cancers are among the most prevalent malignancies in men, posing challenges in treatment and prognosis. This study aimed to evaluate the expression of the oncogenes TOP2A, UBE2C and CKS2 in the bladder (BLCA) and prostate (PRAD) cancers and assess the potential inhibitory effects of sitagliptin through molecular docking. Microarray datasets from the NCBI–GEO database were analyzed to identify differentially expressed genes (DEGs), visualized using volcano plots, UMAP and Venn diagrams. TOP2A, UBE2C and CKS2 expression levels were linked to cancer progression, with mutation and interaction analysis performed using cBioPortal, STRING and GeneMANIA. In silico docking evaluated the binding affinity of sitagliptin, PNU-74654 and Crizotinib. Results showed significant overexpression of TOP2A, UBE2C and CKS2 in advanced stages of BLCA and PRAD, correlating with poorer survival. Sitagliptin exhibited strong binding affinities (−178.98, −125, −112 kcal/mol) to these oncogenes, suggesting its inhibitory potential. PNU-74654 and Crizotinib showed lower binding affinities. This study highlights sitagliptin as a promising therapeutic agent targeting TOP2A, UBE2C and CKS2, with potential to reduce cancer cell proliferation and induce apoptosis. These findings support the development of personalized treatment approaches for bladder and prostate cancer.

  • Exploring the Genetic and Molecular Connection between Autism and Huntington’s Disease via Transcriptomics and Biological Interaction Networks Analysis

    by Muhammad Naveed, Sana Rehman Cheema, Tariq Aziz, Syeda Izma Makhdoom, Urooj Saleem, Hamza Jamil, Majid Alhomrani, Walaa F. Alsanie, Abdulhakeem S. Alamri

    Autism Spectrum Disorder (ASD) and Huntington’s Disease (HD) are distinct neurodevelopmental and neurodegenerative disorders, respectively, characterized by significant genetic and molecular alterations. ASD primarily affects early childhood and is associated with genetic mutations impacting brain development, while HD, an autosomal dominant disorder, leads to progressive neurodegeneration due to mutations in the HTT gene. Despite their differences, both disorders share common genetic pathways and molecular mechanisms. This study aims to explore the genetic and molecular connections between ASD and HD through a comprehensive analysis of differentially expressed genes (DEGs) and protein–protein interaction (PPI) networks to uncover shared pathways and potential overlapping mechanisms. Transcriptomic data were acquired from the NCBI-GEO database, specifically GSE180185 for ASD and GSE1751 for HD. DEGs were identified using thresholds of log2 fold change (FC)>1 and an adjusted [ ]-value <0.05. Common DEGs between the two disorders were determined and analyzed using Cytoscape’s STRING app to construct a PPI network with a confidence level of 0.7. Functional enrichment was conducted through KEGG and Gene Ontology (GO) analyses. Key regulatory modules and hubs were identified using CytoNCA and MCODE plugins. The ASD dataset revealed 565 DEGs, with 206 upregulated and 347 downregulated, while the HD dataset had 1091 DEGs, with 743 upregulated and 202 downregulated. Twelve genes were common to both conditions, including 4 upregulated and 8 downregulated. The PPI network comprised 62 nodes and 215 edges, with significant pathways including ascorbate metabolism and steroid hormone biosynthesis. Notably, Module 3, containing 12 nodes, was linked to EGFR tyrosine kinase resistance and apoptosis. This study identifies shared genetic and molecular pathways between ASD and HD, highlighting common regulatory mechanisms and potential targets for further research. The use of transcriptomic data and PPI network analysis reveals significant overlaps in the molecular mechanisms underlying these disorders. Further experimental validation and expanded dataset analyses could elucidate specific interactions and enhance our understanding of the shared pathways. Investigating these common mechanisms may also provide insights into potential therapeutic approaches for both ASD and HD.


  • Spatially Resolved Transcriptomic Profiling of PRAME Oncogene Expression in Skin Cutaneous Melanoma: Elucidating Dermato-Oncology Therapy through Molecular Docking

    by Muhammad Naveed, Hamza Jamil, Tariq Aziz, Syeda Izma Makhdoom, Muzammil Ur Rehman, Ayaz Ali Khan, Majid Alhomrani, Walaa F. Alsanie, Abdulhakeem S. Alamri

    Background: Skin cutaneous melanoma (SKCM) is a highly aggressive form of skin cancer characterized by rapid metastasis and poor prognosis. PRAME (Preferentially Expressed Antigen in Melanoma) is an oncogene overexpressed in various cancers, including melanoma, and is implicated in tumorigenesis and immune evasion. Understanding the spatial expression patterns of PRAME in SKCM can provide insights into the disease mechanism and therapeutic targets. Aim of the Study: This study aims to spatially resolve the transcriptomic profile of PRAME in SKCM and evaluate the therapeutic potential of selected dermato-oncology agents through molecular docking. Methods: Spatial transcriptomics was performed on SKCM tissue samples from 30 patients to map PRAME expression. Differential expression analysis and spatial clustering were conducted. Molecular docking using HDock assessed the binding affinities of PRAME with dermato-oncology agents: vemurafenib, dioxybenzone and octocrylene, as well as their conjugates (O-D: octocrylene-dioxybenzone, O-V: octocrylene-vemurafenib and D-V: dioxybenzone-vemurafenib). Chemsketch facilitated the creation of conjugates, and Pymol was used for visualization. Results: PRAME was significantly upregulated in SKCM tissues, with a mean expression level of 8.5 TPM compared to 1.2 TPM in normal tissues ([ ] < 0.001). HDock analysis revealed that dioxybenzone had a binding energy of –106.08 kcal/mol, octocrylene –107.04 kcal/mol, and vemurafenib –114.15 kcal/mol. The conjugates showed improved binding affinities: O-D had –142.93 kcal/mol, O-V had –152.69 kcal/mol and D-V had –184.53 kcal/mol, with D-V showing the most substantial binding affinity. Conclusion: Spatial transcriptomic profiling highlights PRAME as a key biomarker in SKCM. The molecular docking results indicate that D-V conjugates (dioxybenzone-vemurafenib) possess the highest binding affinity (–184.53 kcal/mol), suggesting a promising therapeutic potential for SKCM treatment. These findings support further investigation into D-V conjugates as targeted treatments for melanoma. Future Prospects: Future research should focus on in vivo validation of the identified therapeutic agents and exploring the role of PRAME in SKCM pathogenesis. Additionally, combining spatial transcriptomics with other omics data could enhance our understanding of the tumor microenvironment and lead to novel therapeutic approaches.


  • Spatially Resolved Transcriptomics Reveals Local Invasion-Related Genes in Liver Hepatocellular Carcinoma: Exploring the Therapeutic Potential of a Chimeric Protein Targeting Glypican-3

    by Muhammad Naveed, Hamza Jamil, Tariq Aziz, Syeda Izma Makhdoom, Abdulhakeem S. Alamri, Majid Alhomrani, Roaa Mohammed Tahir Kassim, Nehad. A Shaer, Aminah A. Barqawi, Nouf S. Al-Abbas

    Despite advancements in cancer therapy, hepatocellular carcinoma (HCC) remains a major health concern due to late-stage diagnosis and poor prognosis. In this study, the expression of Glypican-3 (GPC3), a cell surface protein encoded by the GPC3 gene was analyzed at both Messenger RNA and protein levels. The goal was to advance understandings into the role of GPC3 in HCC progression and design a fusion protein as a potential therapy targeting cancer cells expressing this oncogene. Expression analysis of GPC3 in liver hepatocellular carcinoma (LIHC) was performed using GEPIA 2 and OncoDB servers. The analysis revealed a significantly high expression level of GPC3 in cancerous tissues of HCC, with a p-value of p = 1.07e-37. This finding indicates the potential involvement of GPC3 in HCC development. To construct the chimeric proteins (CPs), rituximab, a linker, and an approved Anti-Ogawa O-antigen monoclonal antibody S-20-4 penetrating peptide were combined using trRosetta. The peptide sequence of the Anti-Ogawa O-antigen monoclonal antibody S-20-4, namely, NHNYPPLSLLTF, SHDWRLMLSHLQ, QHDRLLMLSYLV, HHILPPKALLFG, SHTFPPSWLLVR and YSVKPPLPYLPP was obtained from the Immunet BDB database. The HDock scoring algorithms were employed to assess the degree of connection between the CP and the GPC3 gene expressed in HCC. The analysis showed a strong binding affinity of -258.53 KJ/mol between the CP and GPC3, indicating a favorable interaction. Simulations and toxicity analysis further supported the therapeutic potential of the constructed CP for treating LIHC. These findings highlight the potential of the CP as a targeted therapy against HCC, leveraging the high expression of GPC3 in cancerous tissues.